Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RegenoGel-OSP
- Development stage
- Phase 4
- Lead developer
- ProCore Bio
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
RegenoGel-OSP is an autologous, intra-articular fibrin-hyaluronan (HA) hydrogel conjugate developed by ProCore Ltd for the treatment of knee osteoarthritis. It is produced by chemically conjugating high molecular weight hyaluronic acid to fibrinogen derived from the patient's own plasma using the proprietary HaProlink™ technology. The product is injected as a non-viscous liquid that distributes throughout the joint space and fills cartilage defects before undergoing in-situ gelation triggered by endogenous thrombin and tissue factors. The resulting stable hydrogel scaffold provides mechanical protection, enhances joint lubrication, and creates a regenerative microenvironment that supports stem cell attachment and cartilage matrix formation. Clinical studies have demonstrated its safety and potential for long-term symptom relief and joint preservation.
- Brand names
- RegenoGel-OSP
- Other names
- fibrin-hyaluronan hydrogelfibrin-HA conjugateautologous plasma-derived fibrinogen-HA conjugate
02
Targets
CD44 (CD44 antigen)ICAM1 (Intercellular Adhesion Molecule 1)GPIIb/IIIa (Integrin alpha-IIb/beta-3)αVβ3 (Integrin αVβ3)LAYN (Layilin)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on RegenoGel-OSP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RegenoGel-OSP.